Beta Bionics Reports Strong Q4 & Full Year 2025 Results, Guides for Continued Growth in 2026
BBNX sits 57% above its 52-week low of $8.89.
Summary
Beta Bionics reported strong Q4 and full year 2025 financial results with significant revenue and customer growth, alongside positive revenue guidance for 2026, and a healthy cash balance.
Key Events · Earnings and Guidance · BBNX
-
Strong Revenue Growth Reported
Net sales for Q4 2025 increased 57% to $32.1 million, and full year 2025 net sales grew 54% to $100.3 million, driven by both DME and PBP channels.
-
Significant Customer Base Expansion
The installed customer base surged 129% year-over-year to 35,011 users, with new patient starts increasing 37% in Q4 2025 and 52% for the full year.
-
Positive 2026 Revenue Guidance
The company introduced full year 2026 revenue guidance of $130 million to $135 million, indicating continued strong growth expectations.
-
Healthy Cash Position
Beta Bionics ended 2025 with $264.7 million in cash, cash equivalents, and investments, providing a strong financial foundation.
Analysis · BBNX · Industrial Applications And Services
Beta Bionics, Inc. announced robust financial results for the fourth quarter and full year 2025, demonstrating significant growth in net sales and its customer base. This performance is particularly notable following the FDA warning letter received on January 30, 2026, indicating the company's operational strength despite regulatory challenges. The company also provided optimistic revenue guidance for 2026, projecting continued strong growth. The healthy cash position at year-end provides a substantial runway for ongoing operations and R&D initiatives, including progress on its bihormonal system.
At the time of this filing, BBNX was trading at $13.97 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $615M. The 52-week trading range was $8.89 to $32.71. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.